Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF<i>V600E</i>-mutant melanoma

Antoneicka L. Harris(Mayo Clinic in Florida), John A. Copland(Jacksonville College)
Oncotarget
December 23, 2017
Cited by 17


Related Papers